Cetuximab is an active treatment of metastatic and chemorefractory thymoma

Frontiers in Bioscience

Volumn 12, Issue 2, 2007, Pages 757-761

  Palmieri, Giovannella ^a   Marino, Mirella ^b   Salvatore, Marco ^a   Budillon, Alfrede ^c   Meo, Giuseppina ^c   Caraglia, Michele ^c   Montella, Liliana ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cetuximab; Chemo refractory; Epidermal growth factor; Epidermal growth factor receptor; Metastatic; Thymoma

Indexed keywords

EID: 34249818183     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/2098     Document Type: Article

References (16)

1. R. Bianco, G. Daniele, F. Ciardiello, G. Tortora: Monoclonal antibodies targeting the epidermal growth factor receptor. Curr Drug Targets 6:275-287 (2005)
2. F. Caponigro, R. Formato, M. Caraglia, N. Normanno, R.V.Iaffaioli: Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors. Curr Opin Oncol 17:212-217 (2005)
3. L.B. Saltz, N.J. Meropol, P.J. Sr. Loehrer, M.N. Needle, J. Kopit, R.J. Mayer Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-8 (2004)
4. N.B. Gilhus, M. Jones, H. Turley, K.C. Gatter, N. Nagvekar, J. Newsom-Davis, N. Willcox: Oncogene proteins and proliferation antigens in thymomas: increased expression of epidermal growth factor receptor and Ki67 antigen. J Clin Pathol 48:447-55 (1995)
5. J.D. Henley, G.K. Koukoulis, P.J. Sr. Loehrer: Epidermal growth factor receptor expression in invasive thymoma. J Cancer Res Clin Oncol 128:167-70 (2002)
6. J. Rosai, L.H.Sobin: Histological typing of tumours of the thymus. In: World Health Organization, International Histological Classification of Tumours. Springer Verlag: Berlin Heidelberg New York 2nd edition (1999)
7. W.D. Travis, E. Brambilla, H.K. Mueller-Hermelink, and C.C. Harris. Tumours of the Lung, Pleura, Thymus and Heart. In: World Health Organization International Classification of Tumour, IARC Press Lyon (2004)
8. A. Masaoka, Y. Monden, K. Nakahara, T. Tanioka: Follow-up study of thymomas with special reference to their clinical stages. Cancer 48:2485-92 (1981)
9. G. Palmieri, L. Montella, A. Martinetti, P. Muto, D. Di Vizio, A. De Chiara, S. Lastoria: Somatostatin analogs and prednisone in advanced refractory thymic tumors. Cancer 94:1414-20 (2002)
10. P. Ströbel, M. Hartmann, A. Jacok, K. Mikesch, I. Brink, S. Dirnhofer, A. Marx: Thymic Carcinoma with Overexpression of Mutated KIT and the Response to Imatinib. N Engl J Med 25:2625-26 (2004)
11. Y. Hayashi, N. Ishii, C. Obayashi, K. Jinnai, K. Hanioka, Y. Imai, H. Itoh: Thymoma: tumour type related to expression of epidermal growth factor (EGF), EGF-receptor, p53, v-erb B and ras p21. Virchows Arch 426:43-50 (1995)
12. D.N. Ionescu, E. Sasatomi, K. Cieply, M. Nola, S. Dacic: Protein expression and gene amplification of epidermal growth factor receptor in thymomas. Cancer 103:630-6 (2005)
13. N.B. Avril, W.A. Weber: Monitoring response to treatment in patients utilizing PET. Radiol Clin North Am 43:189-204 (2005)
14. G.J. Kelloff, J.M. Hoffman, B. Johnson, H.I. Scher, B.A. Siegel, E.Y. Cheng, B.D. Cheson, J. O'shaughnessy, K.Z. Guyton, D.A. Mankoff, L. Shankar, S.M. Larson, C.C. Sigman, R.L. Schilsky, D.C.Sullivan: Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 11:2785-808 (2005)
15. P. Price, T. Jones: Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group. Eur J Cancer 31A:1924-7 (1995)
16. S.N. Reske, J. Kotzerke: FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000. Eur J Nuct Med 28:1707-23 (2001)